BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17597708)

  • 1. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
    Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
    Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of GATA1 mutation in acute megakaryocytic leukemia].
    Ito E
    Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
    [No Abstract]   [Full Text] [Related]  

  • 5. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
    Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
    Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
    [No Abstract]   [Full Text] [Related]  

  • 8. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 9. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder.
    Hasle H; Lund B; Nyvold CG; Hokland P; Østergaard M
    Leuk Res; 2006 May; 30(5):543-6. PubMed ID: 16242775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transient myeloproliferative disorder in a neonate without Down syndrome].
    Adam M; Vincenot A; Gouraud F; Harvel C; Perot C; Portnoi MF; Andre-Kerneis E; Giraudier S; Leverger G; Favier R
    Ann Biol Clin (Paris); 2007; 65(5):569-73. PubMed ID: 17913678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
    Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
    Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
    Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
    Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of GATA1 mutations in Down syndrome.
    Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
    Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
    Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
    Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.
    Kobayashi K; Usami I; Kubota M; Nishio T; Kakazu N
    Cancer Genet Cytogenet; 2005 Apr; 158(2):184-7. PubMed ID: 15796967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.